Treatment of Factitious Hyperthyroidism in Postpartum Thyroiditis (Thyrotoxic Phase)
This protocol covers first-line management of factitious hyperthyroidism presenting in women during the thyrotoxic phase of postpartum thyroiditis — a distinct autoimmune thyroid condition arising in the first year after pregnancy.
Clinical Scenario
Postpartum thyroiditis is an autoimmune condition causing thyroid dysfunction within the first 12 months following a pregnancy in a previously euthyroid woman. The thyrotoxic phase is typically self-limiting, and anti-thyroid drugs are not indicated during this phase. Management focuses on controlling symptoms in women who require treatment while remaining safe for breastfeeding.
Treatment Approach (Partial)
Symptomatic women in the thyrotoxic phase may be considered for beta-blocker therapy — agents with an established safety profile in breastfeeding. The specific choice of agent, dosing guidance, and full decision algorithm are available in the complete structured regimen below.
References
DOI: 10.1089/thy.2016.0229
- Postpartum thyroiditis is an autoimmune condition causing thyroid dysfunction, within the first 12 months following a pregnancy in a previously euthyroid woman.
- Usually self-limiting and anti-thyroid drugs are not indicated in the thyrotoxic phase of post-partum thyroiditis.
- Women in thyrotoxic phase who are symptomatic should be treated with lowest possible dose of b-blockers such as propranolol (40-120mg daily in three divided doses), 20-50mg daily atenolol and metoprolol which are safe in breast feeding.